Budget impact of continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes who experience severe recurrent hypoglycemic episodes in Spain

Giménez, Marga; Elías, Isabel; Álvarez, María; Quirós, Carmen; Conget, Ignacio

doi:10.1016/j.endien.2017.04.010

Cited by 3 publications

(13 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The budget time horizon was concentrated in 1-5 years, which was mainly in accord with the guidelines and the requirements of the budget holders. The most commonly used of time horizon was 3 years (n = 6) (14-17, 19, 23) and 5 years (n = 6) (10-12, 21, 25, 27), followed by 1 year (n = 4) (20,22,24,26) and 4 years (n = 2) (13,18). Notably, two studies also conducted within time-horizons of 24 weeks and 32 weeks based on the study duration of the clinical trials (22,24).…”

Section: Methodology and Budget Results Of Biasmentioning

confidence: 99%

“…About half of the BIA studies (n = 8) evaluated the budget impact of insulin, including basal insulin (n = 5) (13,(20)(21)(22)26), pre-mix insulin (n = 1) ( 16), bolus insulin (n = 1) (24). One study focused on the administration route of insulin (continuous subcutaneous insulin infusion vs. multiple daily insulin injections) instead of the specific type of insulin (18). Among the five basal insulin BIA studies, one of them was about insulin glargine biosimilar (13).…”

Section: Data Extractionmentioning

confidence: 99%

“…The eligible population were mainly chosen according to the indication of intervention and the coverage of the payer's plan. The majority of studies (n = 13) (10-12, 14-17, 19, 22-25, 27) restricted the target population on type 2 diabetes patients while some targeted type 1 diabetes patients (n = 2) (18,21), or type 1 and type 2 diabetes patients (n = 2) (20,26), and one study did not specify the target population (13). Six studies estimated the eligible population size based on a hypothetical health plan (20,(23)(24)(25)(26)(27), of which the assumed size varied widely ranging from 1 million to 35 million.…”

Section: Characteristics Of Literature Includedmentioning

confidence: 99%

“…Ten studies calculated the target populations based on the total population in the country (10-12, 14-17, 19, 21, 22). The rest two studies did not report the size of target population (13,18). Among the 15 studies that reported the specific size of target population, more than half of them (n = 13) calculated the size based on local epidemiological data, while the other two studies calculated the size based on real world evidence (10,22).…”

Section: Characteristics Of Literature Includedmentioning

confidence: 99%

“…It is worth noting that one study applied the patient-years instead of patient number to measure the size of target population (10). Two other characteristics were checked: nine studies (16, 18, 20-24, 26, 27) reported conflict of interests (50%), 12 studies (14,(16)(17)(18)(19)(20)(22)(23)(24)(25)(26)(27) reported pharmaceutical company funding (66.7%), and three studies (10)(11)(12) contained no details of conflicts of interests or funding sources (16.7%).…”

Section: Characteristics Of Literature Includedmentioning

confidence: 99%

See 4 more Smart Citations

Budget Impact Analysis of Diabetes Drugs: A Systematic Literature Review

Luo

Ruan

Yao

et al. 2021

Front. Public Health

View full text Add to dashboard Cite

Background: Budget impact analysis (BIA) is an economic assessment that estimates the financial consequences of adopting a new intervention. BIA is used to make informed reimbursement decisions, as a supplement to cost-effectiveness analyses (CEAs).Objectives: We systematically reviewed BIA studies associated with anti-diabetic drugs and assessed the extent to which international BIA guidelines were followed in these studies.Methods: We conducted a literature search on PubMed, Web of Science, Econlit, Medline, China National Knowledge Infrastructure (CNKI), Wanfang Data knowledge Service platform from database inception to June 30, 2021. ISPOR good practice guidelines were used as a methodological standard for assessing BIAs. We extracted and compared the study characteristics outlined by the ISPOR BIA Task Force to evaluate the guideline compliance of the included BIA.Results: A total of eighteen studies on the BIA for anti-diabetic drugs were identified. More than half studies were from developed countries. Seventeen studies were based on model and one study was based on real-world data. Overall, analysis considered a payer perspective, reported potential budget impacts over 1–5 years. Assumptions were mainly made about target population size, market share uptake of new interventions, and scope of cost. The data used for analysis varied among studies and was rarely justified. Model validation and sensitivity analysis were lacking in the current BIA studies. Rebate analysis was conducted in a few studies to explore the price discount that was required for new interventions to demonstrate cost equivalence to comparators.Conclusion: Existing studies evaluating budget impact for anti-diabetic drugs vary greatly in methodology, some of which showed low compliance to good practice guidelines. In order for the BIA to be useful for assisting in health plan decision-making, it is important for future studies to optimize compliance to national or ISPOR good practice guidelines on BIA. Model validation and sensitivity analysis should also be improved in future BIA studies. Continued improvement of BIA using real-world data is necessary to ensure high-quality analyses and to provide reliable results.

show abstract

Section: Methodology and Budget Results Of Biasmentioning

confidence: 99%

Section: Data Extractionmentioning

confidence: 99%

Section: Characteristics Of Literature Includedmentioning

confidence: 99%

Section: Characteristics Of Literature Includedmentioning

confidence: 99%

Section: Characteristics Of Literature Includedmentioning

confidence: 99%

See 3 more Smart Citations

Budget Impact Analysis of Diabetes Drugs: A Systematic Literature Review

Luo

Ruan

Yao

et al. 2021

Front. Public Health

View full text Add to dashboard Cite

show abstract

Use of insulin pumps and closed‐loop systems among people living with diabetes: A narrative review of clinical and cost‐effectiveness to enable access to technology and meet the needs of payers

Jendle

Reznik

2023

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

The use of continuous subcutaneous insulin infusion (CSII) via insulin pumps is today considered standard of care for type 1 diabetes (T1D). Closed-loop systems combining continuous glucose monitoring with automated algorithm-driven insulin delivery have been shown to be safe and efficacious in randomized controlled trials and reallife studies in both paediatric and adult participants with T1D. Implementation of hybrid closed-loop (HCL) systems has shown incremental effectiveness, with further reduction of hypoglycaemia and hyperglycaemia. Although less extensively studied in type 2 diabetes (T2D), insulin pumps have demonstrated their effectiveness in glucose control, along with a reduction in need for insulin and a neutral effect on weight.Recent studies have also shown promising results with the use of HCL systems in T2D. Cost-effectiveness studies in both T1D and T2D have shown that pump use is cost-effective in several countries, leading to improvements in quality-adjusted lifeyears. Insulin pumps are currently reimbursed for T1D in many European countries, but in only a few for individuals with T2D. HCL systems are to be evaluated in future trials performed in T2D to compare their incremental efficacy and cost-effectiveness in comparison with available intensification tools which include multiple daily insulin injections, metformin, sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. There is a need for updated guidelines for the use of CSII and HCL in individuals living with T2D based on the emerging evidence, with identification of and recommendations for the people who would benefit the most, which would eventually form a basis for reimbursement and health policies. K E Y W O R D S continuous glucose monitoring (GCM), cost-effectiveness, CSII, insulin pump therapy, type 2 diabetes This article has an accompanied Plain Language Summary in the Supporting Information Data S1.

show abstract

Table_1.docx

View full text Add to dashboard Cite

Budget impact of continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes who experience severe recurrent hypoglycemic episodes in Spain

Cited by 3 publications

References 15 publications

Budget Impact Analysis of Diabetes Drugs: A Systematic Literature Review

Budget Impact Analysis of Diabetes Drugs: A Systematic Literature Review

Use of insulin pumps and closed‐loop systems among people living with diabetes: A narrative review of clinical and cost‐effectiveness to enable access to technology and meet the needs of payers

Table_1.docx

Contact Info

Product

Resources

About